ERBB2 and breast cancer: Whereas, BC with HER2-low-expression status who were previously classified into the HER2-negative expression group would benefit from novel HER2-targeted antibody-drug conjugate (ADC), such as trastuzumab deruxtecan (T-DXd) [4, 24].